{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:57:23Z","timestamp":1791241043787,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13975-3","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:02:16Z","timestamp":1783630936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors of multi-drug-resistant tuberculosis among tuberculosis patients in Bagmati Province, Nepal: a matched case-control study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8235-0762","authenticated-orcid":false,"given":"Puspa","family":"Acharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niraj","family":"Bhattarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuban Raj","family":"Kunwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajan","family":"Bhusal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreesti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khem Raj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay Kumar","family":"Khanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birendra Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"13975_CR1","unstructured":"World Health Organization. 2025. Licence: CC BY-NC-SA 3.0 IGO. Global Tuberculosis Report 2025. 2025."},{"key":"13975_CR2","unstructured":"Institute of Health Metrix and Evaluations [IHME]. Findings from the global burden of disease study 2017. Seattle, WA: IHME. 2018. Lancet. 2017."},{"key":"13975_CR3","doi-asserted-by":"crossref","unstructured":"Rock D. Tuberculosis: a global emergency. Work [Internet]. 1997;8(1):93\u2013105. Available from: https:\/\/www.medra.org\/servlet\/aliasResolver?alias=iospress&doi=10.3233\/WOR-1997-8111","DOI":"10.3233\/WOR-1997-8111"},{"key":"13975_CR4","unstructured":"World Health Organization. What is DOTS ? A guide to understanding the WHO-recommended TB control strategy known as DOTS. Prev Control [Internet]. 1999;1\u201339. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/65979."},{"key":"13975_CR5","unstructured":"Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, et al. Building a tuberculosis-free world: the lancet commission on tuberculosis. Lancet [Internet]. 2019;393(10178):1331\u201384. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673619300248."},{"key":"13975_CR6","unstructured":"WHO. Follow-up to the high-level meetings of the UN general assembly on health-related issues AMR report by the director-general. Seventy-second World Heal Assem [Internet]. 2019;(April):1\u201311. Available from: https:\/\/amrcountryprogress.org."},{"key":"13975_CR7","unstructured":"Tb D. Focus on Drug-resistant Tuberculosis. Glob Fund 2019 [Internet]. 2019; Available from: https:\/\/www.theglobalfund.org\/media\/6651\/publication_drug-resistanttuberculosis_focuson_en.pdfu636450358380000000."},{"key":"13975_CR8","unstructured":"GON MOHP, DOHS NTCC. National tuberculosis program Nepal. NTCC, editor. Vol. 75, Annual Report. Bhaktapur: NTC; 2018. 1\u201330 p."},{"key":"13975_CR9","unstructured":"World Health Organization. Consolidated guidelines on tuberculosis treatment. Who. 2019."},{"key":"13975_CR10","doi-asserted-by":"publisher","unstructured":"Law S, Piatek AS, Vincent C, Oxlade O, Menzies D. Emergence of drug resistance in patients with tuberculosis cared for by the Indian healthcare system: a dynamic modelling study. Lancet Public Heal [Internet]. 2017;2(1):e47\u201355. Available from: https:\/\/doi.org\/10.1016\/S2468-2667(16)30035-4.","DOI":"10.1016\/S2468-2667(16)30035-4"},{"key":"13975_CR11","unstructured":"WHO. Global tuberculosis report 2019. Geneva: World Health Organization. 2019. Licence: CC BY-NC-SA 3.0 IGO. 2019."},{"key":"13975_CR12","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1021\/ci400128m","volume":"53","author":"WHO. ENDING TB IN SEAR","year":"2013","unstructured":"WHO. ENDING TB IN SEAR. Regional strategic plan 2016\u20132020. J Chem Inf Model. 2013;53:1689\u201399.","journal-title":"J Chem Inf Model"},{"key":"13975_CR13","unstructured":"The Economist Intelligence Unit. It\u2019s time to end drug-resistant tuberculosis. The case for action. 2019;1\u201339. Available from: http:\/\/www.eiu.com\/graphics\/marketing\/pdf\/its-time-to-end-drug-resistant-tuberculosis-full-report.pdf."},{"key":"13975_CR14","unstructured":"Department of Health, Services M. Government of Nepal M of H and P. Annual Health Report FY 2080\/81."},{"key":"13975_CR15","unstructured":"Government of nepal M of H and P, National tubrculosis control center. Training manual for medical doctors - drug resistant TB. 2024."},{"issue":"2","key":"13975_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3126\/saarctb.v16i2.23337","volume":"16","author":"SK Shrestha","year":"2018","unstructured":"Shrestha SK, Shah NP, Jha KK, Pant RP, Joshi LR, Bichha RP, et al. Challenges in the diagnosis of drug-resistant tuberculosis by GeneXpert MTB\/Rif in Nepal. SAARC J Tuberc Lung Dis HIV\/AIDS. 2018;16(2):8\u201315.","journal-title":"SAARC J Tuberc Lung Dis HIV\/AIDS"},{"issue":"4","key":"13975_CR17","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s13149-015-0443-4","volume":"108","author":"T Comolet","year":"2015","unstructured":"Comolet T. La tuberculose \u00e0 bacilles multi-r\u00e9sistants: d\u00e9fis d\u2019une \u00e9mergence globale. Bull la Soc Pathol Exot. 2015;108(4):290\u20138.","journal-title":"Bull la Soc Pathol Exot"},{"issue":"3","key":"13975_CR18","first-page":"1","volume":"5","author":"V Bhatia","year":"2020","unstructured":"Bhatia V, Srivastava R, Reddy KS, Sharma M, Mandal PP, Chhabra N, et al. Ending TB in Southeast Asia: Current resources are not enough. BMJ Glob Heal. 2020;5(3):1\u201311.","journal-title":"BMJ Glob Heal"},{"key":"13975_CR19","unstructured":"Ending TB. Invest now or pay later. New Delhi: World Health Organization, Regional office for Southeast Asia; 2018. Licence: CC BY-NC- SA 3.0 IGO. 2018."},{"key":"13975_CR20","unstructured":"NATA. https:\/\/www.antitb.org.np\/#"},{"key":"13975_CR21","unstructured":"Jantra \u2013 Enhancing social welfare in Nepal. https:\/\/www.jantra.org.np\/."},{"key":"13975_CR22","unstructured":"Nepal TB control center. https:\/\/nepalntp.gov.np\/."},{"key":"13975_CR23","doi-asserted-by":"crossref","unstructured":"Abdella K, Abdissa K, Kebede W, Abebe G. Drug resistance patterns of Mycobacterium tuberculosis complex and associated factors among retreatment cases around Jimma, Southwest Ethiopia. BMC Public Health [Internet]. 2015 Jul 2 [cited 2021 Mar 9];15(1):599. Available from: http:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-015-1955-3.","DOI":"10.1186\/s12889-015-1955-3"},{"key":"13975_CR24","doi-asserted-by":"crossref","unstructured":"Ali MH, Alrasheedy AA, Hassali MA, Kibuule D, Godman B. Predictors of multidrug-resistant tuberculosis (MDR-TB) in Sudan. Antibiotics. 2019;8(3).","DOI":"10.3390\/antibiotics8030090"},{"issue":"4","key":"13975_CR25","first-page":"536","volume":"5","author":"O Korotych","year":"2019","unstructured":"Korotych O, Hovhannisyan A, Zaitseva O, Denisuk O, Dadu A, Dara M. Risk factors associated with RR\/MDR-TB among new pulmonary tuberculosis patients in urban and rural areas of Ukraine in 2017: retrospective analysis of routine surveillance data. Public Heal Panor. 2019;5(4):536\u201347.","journal-title":"Public Heal Panor"},{"issue":"5","key":"13975_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijerph16050738","volume":"16","author":"L Liu","year":"2019","unstructured":"Liu L, Zhang X, Zhao L, Li N. Empirical analysis of the status and influencing factors of catastrophic health expenditure of migrant workers in Western China. Int J Environ Res Public Health. 2019;16(5):1\u201310.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"13975_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4102\/ajlm.v7i2.781","volume":"7","author":"N Ismail","year":"2018","unstructured":"Ismail N, Ismail F, Omar SV, Blows L, Gardee Y, Koornhof H, et al. Drug resistant tuberculosis in Africa: Current status, gaps and opportunities. Afr J Lab Med. 2018;7(2):1\u201311.","journal-title":"Afr J Lab Med"},{"key":"13975_CR28","doi-asserted-by":"crossref","unstructured":"Li W, Bin, Zhang YQ, Xing J, Ma ZY, Qu YH, Li XX. Factors associated with primary transmission of multidrug-resistant tuberculosis compared with healthy controls in Henan Province, China. Infect Dis Poverty [Internet]. 2015 Mar 24 [cited 2021 Mar 8];4(1):14. Available from: https:\/\/idpjournal.biomedcentral.com\/articles\/10.1186\/s40249-015-0045-1.","DOI":"10.1186\/s40249-015-0045-1"},{"key":"13975_CR29","doi-asserted-by":"crossref","unstructured":"Escombe AR, Oeser CC, Gilman RH, Navincopa M, Ticona E, Pan W, et al. Natural ventilation for the prevention of airborne contagion. PLOS Med [Internet]. 2007 [cited 2021 Mar 9];4(2):e68. Available from: https:\/\/journals.plos.org\/plosmedicine\/articleid10.1371\/journal.pmed.0040068.","DOI":"10.1371\/journal.pmed.0040068"},{"issue":"4","key":"13975_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0214235","volume":"14","author":"E Shimeles","year":"2019","unstructured":"Shimeles E, Enquselassie F, Aseffa A, Tilahun M, Mekonen A, Wondimagegn G, et al. Risk factors for tuberculosis: A case\u2013control study in Addis Ababa, Ethiopia. PLoS ONE. 2019;14(4):1\u201318.","journal-title":"PLoS ONE"},{"issue":"2","key":"13975_CR31","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3904\/kjim.2014.29.2.183","volume":"29","author":"SS Hwang","year":"2014","unstructured":"Hwang SS, Kang S, Lee JY, Lee JS, Kim HJ, Han SK, et al. Impact of outdoor air pollution on the incidence of tuberculosis in the Seoul metropolitan area, South Korea. Korean J Intern Med. 2014;29(2):183\u201390.","journal-title":"Korean J Intern Med"},{"issue":"2","key":"13975_CR32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.4314\/ahs.v15i2.9","volume":"15","author":"W Mulu","year":"2015","unstructured":"Mulu W, Mekonnen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug resistant tuberculosis patients in amhara national regional state. Afr Health Sci [Internet]. 2015;15(2):368\u201377. Available from: \/pmc\/articles\/PMC4480497\/.","journal-title":"Afr Health Sci [Internet]"},{"key":"13975_CR33","doi-asserted-by":"crossref","unstructured":"Gaude G, Hattiholli J, Kumar P. Risk factors and drug-resistance patterns among pulmonary tuberculosis patients in northern Karnataka region, India. Niger Med J [Internet]. 2014 [cited 2021 Mar 9];55(4):327. Available from: http:\/\/www.nigeriamedj.com\/text.asp2014\/55\/4\/327\/137194.","DOI":"10.4103\/0300-1652.137194"},{"key":"13975_CR34","doi-asserted-by":"publisher","unstructured":"Chuchottaworn C, Thanachartwet V, Sangsayunh P, Than TZM, Sahassananda D, Surabotsophon M, et al. Risk factors for multidrug-resistant tuberculosis among patients with pulmonary tuberculosis at the Central Chest Institute of Thailand. Munderloh UG, editor. PLoS One [Internet]. 2015 Oct 7 [cited 2021 Mar 9];10(10):e0139986. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0139986.","DOI":"10.1371\/journal.pone.0139986"},{"issue":"6","key":"13975_CR35","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1371\/journal.pone.0217597","volume":"14","author":"S Glasauer","year":"2019","unstructured":"Glasauer S, Altmann D, Hauer B, Brodhun B, Haas W, Perumal N. First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008\u20132017. PLoS ONE. 2019;14(6):2008\u201317.","journal-title":"PLoS ONE"},{"issue":"6","key":"13975_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0197737","volume":"13","author":"EA Mesfin","year":"2018","unstructured":"Mesfin EA, Beyene D, Tesfaye A, Admasu A, Addise D, Amare M, et al. Drug-resistance patterns of mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia. PLoS ONE. 2018;13(6):1\u201316.","journal-title":"PLoS ONE"},{"issue":"10","key":"13975_CR37","doi-asserted-by":"publisher","first-page":"e110461","DOI":"10.1371\/journal.pone.0110461","volume":"9","author":"P Isaakidis","year":"2014","unstructured":"Isaakidis P, Das M, Kumar AMV, Peskett C, Khetarpal M, Bamne A, et al. Alarming levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai, India. PLoS ONE. 2014;9(10):e110461.","journal-title":"PLoS ONE"},{"key":"13975_CR38","doi-asserted-by":"publisher","unstructured":"Baya B, Achenbach CJ, Kone B, Toloba Y, Dabitao DK, Diarra Bm, et al. Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. Int J Infect Dis [Internet]. 2019 Apr 1 [cited 2021 Mar 9];81:149\u201355. Available from: https:\/\/doi.org\/10.1016\/j.ijid.2019.02.004.","DOI":"10.1016\/j.ijid.2019.02.004"},{"key":"13975_CR39","doi-asserted-by":"crossref","unstructured":"Eshetie S, Gizachew M, Dagnew M, Kumera G, Woldie H, Ambaw F, et al. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC Infect Dis. 2017;17(1).","DOI":"10.1186\/s12879-017-2323-y"},{"issue":"3","key":"13975_CR40","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0929-6646(08)60145-X","volume":"107","author":"WJ Su","year":"2008","unstructured":"Su WJ, Feng JY, Huang CC, Perng RP. Increasing drug resistance of Mycobacterium tuberculosis isolates in a medical center in northern Taiwan. J Formos Med Assoc. 2008;107(3):259\u201364.","journal-title":"J Formos Med Assoc"},{"key":"13975_CR41","unstructured":"Bhattarai S, Awale S. Contributing factors associated with multidrug-resistant tuberculosis among MDR-TB clients of Kathmandu, Nepal. Int J Health Sci Res. 2017;7(7):164\u201370. https:\/\/www.ijhsr.org\/IJHSR_Vol.7_Issue.7_July2017\/24.pdf"},{"key":"13975_CR42","doi-asserted-by":"publisher","first-page":"ii43","DOI":"10.1093\/heapol\/czx093","volume":"32","author":"MS Khan","year":"2017","unstructured":"Khan MS, Hutchison C, Coker RJ, Yoong J, Hane KM, Innes AL, et al. Preventing emergence of drug resistant tuberculosis in Myanmar\u2019s transitioning health system. Health Policy Plan. 2017;32:ii43\u201350.","journal-title":"Health Policy Plan"},{"issue":"1","key":"13975_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-13-782","volume":"13","author":"S Hirpa","year":"2013","unstructured":"Hirpa S, Medhin G, Girma B, Melese M, Mekonen A, Suarez P, et al. Determinants of multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis Ababa: A case control study. BMC Public Health. 2013;13(1):1\u20139.","journal-title":"BMC Public Health"},{"key":"13975_CR44","doi-asserted-by":"crossref","unstructured":"Gobena D, Ameya G, Haile K, Abreha G, Worku Y, Debela T. Predictor of multidrug resistant tuberculosis in southwestern part of Ethiopia: a case control study. Ann Clin Microbiol Antimicrob. 2018;17(1).","DOI":"10.1186\/s12941-018-0283-8"},{"issue":"3","key":"13975_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0118919","volume":"10","author":"S Moyo","year":"2015","unstructured":"Moyo S, Cox HS, Hughes J, Daniels J, Synman L, De Azevedo V, et al. Loss from treatment for drug resistant tuberculosis: Risk factors and patient outcomes in a community-based program in khayelitsha, South Africa. PLoS ONE. 2015;10(3):1\u201313.","journal-title":"PLoS ONE"},{"key":"13975_CR46","doi-asserted-by":"crossref","unstructured":"Demile B, Zenebu A, Shewaye H, Xia S, Guadie A. Risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and teaching hospital, Ethiopia. BMC Infect Dis. 2018;18(1).","DOI":"10.1186\/s12879-018-3167-9"},{"key":"13975_CR47","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/IDR.S126274","volume":"10","author":"A Workicho","year":"2017","unstructured":"Workicho A, Kassahun W, Alemseged F. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients: A case-control study. Infect Drug Resist. 2017;10:91\u20136.","journal-title":"Infect Drug Resist"},{"issue":"9","key":"13975_CR48","doi-asserted-by":"publisher","first-page":"168","DOI":"10.21037\/atm.2016.05.09","volume":"4","author":"K Guenaoui","year":"2016","unstructured":"Guenaoui K, Harir N, Ouardi A, Zeggai S, Sellam F, Bekri F, et al. Use of GeneXpert Mycobacterium tuberculosis\/rifampicin for rapid detection of rifampicin resistant Mycobacterium tuberculosis strains of clinically suspected multidrug resistance tuberculosis cases. Ann Transl Med. 2016;4(9):168.","journal-title":"Ann Transl Med"},{"key":"13975_CR49","doi-asserted-by":"crossref","unstructured":"Stosic M, Vukovic D, Babic D, Antonijevic G, Foley KL, Vujcic I, et al. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients in Serbia: a case-control study. BMC Public Health [Internet]. 2018 Sep 12 [cited 2021 Mar 9];18(1):1114. Available from: https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-018-6021-5.","DOI":"10.1186\/s12889-018-6021-5"},{"key":"13975_CR50","doi-asserted-by":"crossref","unstructured":"Baral SC, Aryal Y, Bhattrai R, King R, Newell JN. The importance of providing counselling and financial support to patients receiving treatment for multidrug resistant TB: mixed method qualitative and pilot intervention studies. BMC Public Health [Internet]. 2014 Jan 17 [cited 2021 Mar 15];14(1):46. Available from: http:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/1471-2458-14-46.","DOI":"10.1186\/1471-2458-14-46"},{"issue":"12","key":"13975_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0082943","volume":"8","author":"S Tang","year":"2013","unstructured":"Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: Retrospective multi-center investigation. PLoS ONE. 2013;8(12):1\u20138.","journal-title":"PLoS ONE"},{"issue":"1","key":"13975_CR52","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12889-016-2711-z","volume":"16","author":"C Zhang","year":"2016","unstructured":"Zhang C, Wang Y, Shi G, Han W, Zhao H, Zhang H, et al. Determinants of multidrug-resistant tuberculosis in Henan province in China: a case control study. BMC Public Health. 2016;16(1):42.","journal-title":"BMC Public Health"},{"key":"13975_CR53","doi-asserted-by":"publisher","unstructured":"Welekidan LN, Skjerve E, Dejene TA, Gebremichael MW, Brynildsrud O, Agdestein A, et al. Characteristics of pulmonary multidrug-resistant tuberculosis patients in Tigray Region, Ethiopia: a cross-sectional study. Quinn F, editor. PLoS One [Internet]. 2020 Aug 14 [cited 2021 Mar 9];15(8):e0236362. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0236362.","DOI":"10.1371\/journal.pone.0236362"},{"issue":"11","key":"13975_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0027610","volume":"6","author":"K Chung-Delgado","year":"2011","unstructured":"Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Velez-Segovia E, Soria-Montoya A, Nu\u00f1ez-Garbin A, et al. Factors associated with anti-tuberculosis medication adverse effects: A case-control study in Lima, Peru. PLoS ONE. 2011;6(11):1\u20135.","journal-title":"PLoS ONE"},{"key":"13975_CR55","doi-asserted-by":"publisher","first-page":"e2019014","DOI":"10.4178\/epih.e2019014","volume":"41","author":"AH Elduma","year":"2019","unstructured":"Elduma AH, Mansournia MA, Foroushani AR, Ali HMH, Elegail AMA, Elsony A, et al. Assessment of the risk factors associated with multidrug-resistant tuberculosis in Sudan: a case-control study. Epidemiol Health. 2019;41:e2019014.","journal-title":"Epidemiol Health"},{"issue":"2","key":"13975_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3126\/saarctb.v14i2.19335","volume":"14","author":"RP Bichha","year":"2018","unstructured":"Bichha RP, Jha KK, Salhotra VS, Weerakoon AP, Karki KB, Bichha N. An Epidemiological Study to Find out Risk Factors of Multi Drugs Resistance Tuberculosis in Nepal. SAARC J Tuberc Lung Dis HIV\/AIDS. 2018;14(2):31\u20138.","journal-title":"SAARC J Tuberc Lung Dis HIV\/AIDS"},{"issue":"04","key":"13975_CR57","doi-asserted-by":"publisher","first-page":"84","DOI":"10.14745\/ccdr.v46i04a05","volume":"46","author":"T Hirama","year":"2020","unstructured":"Hirama T, Sabur N, Derkach P, McNamee J, Song H, Marras T, et al. Risk factors for drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010\u20132016. Can Commun Dis Rep. 2020;46(04):84\u201392.","journal-title":"Can Commun Dis Rep"},{"key":"13975_CR58","doi-asserted-by":"publisher","unstructured":"Marahatta SB, Kaewkungwal J, Ramasoota P, Singhasivanon P. Risk factors of multidrug resistant tuberculosis in central Nepal: a pilot study. Kathmandu Univ Med J (KUMJ). 2010 Oct-Dec;8(32):392-7. https:\/\/doi.org\/10.3126\/kumj.v8i4.6238. PMID: 22610768.","DOI":"10.3126\/kumj.v8i4.6238"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13975-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13975-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13975-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:45:48Z","timestamp":1791240348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13975-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13975"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13975-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"17 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Institutional Review Committee (IRC) of BP Koirala Institute of Health Sciences (BPKIHS), Dharan, with Ref no: IRC\/1981\/020. An original copy of the ethical approval has been submitted as related files. Prior to the beginning of the study, informed consent was obtained from all participants. For those under 18, informed consent was also obtained from the DOTS center for individuals residing at the TB center and from parents or legal guardians for those visiting the DOTS center daily. For any participant under the age of 16, informed consent to participate was provided by their parent or legal guardian. Their privacy, anonymity, and confidentiality were rigorously maintained throughout the study. Permission to conduct the research was also obtained from the National Tuberculosis Control Centre, Bhaktapur. The participants\u2019 identities were anonymised in all study records, and data confidentiality was ensured in accordance with ethical standards.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1771"}}